In a recent transaction, Helen M. Thackray, Chief R&D Officer of Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX), acquired shares of the company's common stock. The purchase, dated May 14, 2024, involved 30,000 shares at a weighted average price of $5.86 per share, with the total transaction amounting to $175,800.
The acquisition was made in multiple transactions with prices ranging from $5.84 to $5.86. Following this purchase, Thackray's ownership in Biocryst Pharmaceuticals has increased to a total of 272,139 shares.
Investors often monitor insider buying and selling as it can provide insights into a company's future prospects or the executives' confidence in the firm's performance. The buying and selling of shares by corporate insiders are routine and are disclosed to the public through filings with the Securities and Exchange Commission.
Biocryst Pharmaceuticals specializes in the development of novel, oral, and small-molecule medicines for rare diseases. With a focus on clinical development, the company aims to address unmet medical needs in areas such as hereditary angioedema and other complement-mediated diseases.
As of the date of the transaction, the stock price for Biocryst Pharmaceuticals has seen fluctuations, and insider transactions such as Thackray's purchase could be of interest to shareholders and potential investors. It's important to note that the motivations behind insider transactions can vary and may not always be indicative of the company's long-term trajectory.
For those interested in the specifics of the trading activity, further details regarding the number of shares bought at each price point within the range can be provided upon request by the issuer, any security holder of the issuer, or the SEC staff.
InvestingPro Insights
In light of Helen M. Thackray's recent stock purchase, it's worth examining Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) through the lens of current market data and analysis available from InvestingPro. As of the last twelve months leading up to Q1 2024, Biocryst Pharmaceuticals has reported revenue growth of 22.68%, with a notable quarterly revenue growth of 34.87% in Q1 2024. Despite these positive growth figures, analysts have flagged concerns about the company's profitability, as reflected by a negative P/E ratio of -6.17 and an operating income margin of -23.88%.
The company's stock price has been quite volatile, with a strong return over the last month of 14.78%, although the price has dropped by 38.88% over the last year. This volatility may be of interest to investors who track price movements for potential buying opportunities. Additionally, Biocryst Pharmaceuticals' liquid assets exceed its short-term obligations, which could be a reassuring sign of financial stability for investors.
An InvestingPro Tip to consider is that analysts do not expect the company to be profitable this year, which may influence investment decisions. Another noteworthy point is that the company does not pay a dividend, which might be a factor for income-focused investors. For more in-depth analysis and additional InvestingPro Tips, interested readers can explore the full suite of insights available at https://www.investing.com/pro/BCRX. There are currently 6 additional InvestingPro Tips listed to help investors make informed decisions. To access these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
With the next earnings date set for August 1, 2024, investors will be closely watching for any changes in the company's financial health and future outlook. The fair value of the stock, as assessed by analysts, currently stands at 11 USD, while InvestingPro's fair value estimate is at 5.16 USD, which may suggest different perspectives on the stock's valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.